** opening soon

** UCI 10-10
Collecting Brain Tumor Specimens for Glioma Vaccine (Bota)

** UCI 12-18
Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments (Bota)

** UCI 16-54
Identification of Functional MRI, Neuropsychiatric, and Circulating VEGF Changes after Marizomib Treatment in Patients Enrolled in the UCI 14-58 study and UCI 16-55 study (Bota)

** UCI 16-89**
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) – Phase IIb Clinical Study (Bota)

** EAF151
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma (Chow)

** UCI 17-13
VIGILANT: Registry to Collect Safety/Efficacy Info of Gliadel Wafer Used in Medical Practice (Carrillo)

---

** ACOSOG A221101
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme (Carrillo)

** UCI 15-79
Phase II Open-label randomized study of radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 brain metastases from NSCLC (Carrillo)

** UCI 16-74
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)
**Brain Cancer Clinical Trials**

**UCI 14-55**
Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

**NRG BN001**
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (Kong)

**UCI 16-56**
Ph II Study of Optune in Bevacizumab-Naive Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

**UCI 17-35**
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

**UCI 14-58**
Phase 1, Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naive Subjects with WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab (Bota)

**RTOG 3503**
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

**UCI 16-22**
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

**SWOG S1609**
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Seery)

**ECOG-EAY131**
Molecular Analysis for Therapy Choice – MATCH (Seery)

**UCI 15-99**
Open-Label, Non-Randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Primary CNS Lymphoma (Bota)

**ALLIANCE A071401**
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Carrillo)

**UCI 13-14**
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

**UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

**** opening soon